China’s New GMP Takes Effect Nov 1, 2026, as NMPA Issues Four New Inspection Guidelines

China’s revised Good Manufacturing Practice (GMP) for medical devices will take effect on November 1, 2026, marking the most substantial update to the country’s device manufacturing regulation since the original 2014 version. Ahead of that effective date, the NMPA has issued four category-specific inspection guidelines on October 28, 2026 that will be used to determine compliance for sterile devices, implantable devices, IVD reagents, and custom-made dentures.

The notice states that “the revised GMP will be implemented from November 1, 2026. To better guide production inspection work for sterile, implantable, in vitro diagnostic reagent, and custom-made denture devices, NMPA has revised the corresponding inspection guidelines and issued the four documents. These four guidelines will also take effect on November 1, 2026”.

Importantly, the notice confirms that from November 1, 2026, NMPA and provincial MPAs will use the newly revised inspection guidelines to determine the results of production license verification and post-market supervisory inspections for sterile, implantable, in vitro diagnostic reagent, and custom-made denture medical devices. The previous inspection guidelines issued in 2015 and 2016 will be simultaneously repealed.

For overseas manufacturers, this is not merely a domestic Chinese compliance update. Even companies producing devices entirely outside China will increasingly feel the impact through registration expectations, supply-chain cooperation with Chinese partners, local manufacturing or finishing arrangements, and inspection readiness. The revised GMP, together with the new inspection guidelines, raises the bar for quality governance, validation discipline, supplier oversight, and lifecycle management.

Early preparation significantly reduces compliance risk and avoids last-minute operational disruptions.

China Med Device, LLC helps overseas manufacturers navigate regulatory updates, evaluate compliance readiness, and build quality systems aligned with China’s GMP environment and your inspection needs.

For support with GMP transition planning or readiness gap assessments, please email us at info@ChinaMedDevice.com

For our recorded training webinar on NMPA GMP, please click HERE

For our successful GMP support case, please click HERE

For NMPA inspection results of overseas manufacturers, click HERE

For 2025 regulation of “Production of Imported Medical Devices”, please click HERE

For our comprehensive review on the “Made-in-China” policy, click HERE

Overview of New GMP Framework

At a structural level, the revised GMP represents a major expansion in scope and regulatory depth.

Key high-level updates include:

• Effective date: November 1, 2026
• Structural expansion: Reorganized into 15 chapters and 132 articles
• Scope extension: Full lifecycle coverage, including outsourced R&D, contract manufacturing, external processing, and entrusted testing
• Compliance focus: Stronger requirements for quality assurance, personnel qualifications, facilities, supplier management, and digital documentation
• Applicability: Impacts both domestic manufacturers and overseas companies using Chinese partners or supply-chain services

Compared to the 2014 version, which primarily emphasized production-stage quality control, the new GMP shifts toward end-to-end lifecycle governance, integrating design, risk management, post-market feedback, and supplier oversight into a unified regulatory framework.

This transformation reflects China’s regulatory modernization agenda and its push toward high-quality, innovation-driven manufacturing under national industrial policies such as “Made in China” and intelligent manufacturing initiatives.

Three Newly Introduced Chapters on Quality Assurance, Validation and Verification, and Contract Manufacturing

One of the most structural changes in China’s new GMP revision is the formal introduction of three new standalone chapters dedicated to Quality Assurance, Validation and Verification, and Contract Manufacturing and Outsourced Activities. Unlike the 2014 GMP, where these topics were scattered across general production requirements, the new framework elevates them into independent regulatory modules with clearer accountability, prescriptive controls, and inspection-ready expectations. Together, these additions reflect the regulator’s shift toward system-level quality governance, process reliability assurance, and full supply chain transparency.

The newly added Quality Assurance (QA) chapter establishes QA as a core governance function rather than a supporting operational role. The regulation requires manufacturers to build a structured, management-driven quality oversight system that spans the full product lifecycle. Key regulatory expectations include:

• Establishment of a formal QA system covering design, production, distribution, and post-market activities
• Lifecycle risk management supported by continuous data collection, trend analysis, and periodic management review
• Structured change control mechanisms requiring documented risk assessment, approval workflows, and verification when applicable
• Clear assignment of management responsibilities for quality decision-making and regulatory compliance

This change significantly increases leadership accountability and reinforces the independence of quality functions from production operations. For overseas manufacturers working with Chinese OEMs or local manufacturing partners, it also raises expectations for quality agreements, audit coordination, and alignment between global QMS frameworks and China-specific GMP documentation.

The newly introduced Validation and Verification chapter strengthens regulatory control over manufacturing reproducibility and technical consistency. Rather than focusing only on end-product inspection, the revised GMP emphasizes scientific validation of critical processes and systematic verification of design and production outputs. Manufacturers are now expected to:

• Validate critical production processes and special processes that cannot be fully verified through routine inspection
• Maintain documented evidence of equivalency when transferring technologies across sites or jurisdictions
• Perform revalidation following significant changes in equipment, materials, software, or production parameters
• Integrate validation activities into formal lifecycle change management systems

For multinational companies implementing parallel manufacturing lines or transferring production from overseas facilities to China, this means higher scrutiny of process comparability studies, performance qualification data, and cross-site validation strategies. Regulators increasingly expect manufacturers to demonstrate not only functional compliance, but long-term process stability under commercial-scale production conditions.

In parallel, the addition of a dedicated Contract Manufacturing and Outsourced Activities chapter formally brings external production and service providers under direct GMP regulatory control. Activities such as outsourced R&D, sterilization services, packaging operations, external processing, and entrusted testing are now explicitly regulated within the GMP framework. The regulation clearly defines that registrants retain ultimate responsibility for compliance performance across the entire supply chain. Core requirements include:

• Mandatory quality agreements defining technical responsibilities, quality standards, deviation handling, and change notification procedures
• Two-way oversight mechanisms, including routine audits, performance monitoring, and corrective action tracking
• Formal communication channels for reporting deviations, complaints, and quality incidents
• Clear separation of production release responsibilities and market release authority, which cannot be subcontracted

For overseas manufacturers relying on Chinese contract manufacturers, sterilization providers, packaging facilities, or testing laboratories, this introduces higher expectations for supplier qualification, documentation harmonization, audit readiness, and cross-border quality governance structures. Supply chain transparency is increasingly becoming a primary inspection focus rather than a secondary compliance element.

Taken together, the addition of these three new chapters signals a decisive regulatory upgrade in China’s GMP system. Quality governance, validation discipline, and outsourced manufacturing control are now positioned as independent but interconnected regulatory pillars. Overseas manufacturers will need to move beyond fragmented compliance approaches and adopt an integrated, lifecycle-oriented quality strategy to remain competitive and inspection-ready under China’s evolving GMP environment.

Comparison Overview: 2014 GMP vs. 2025 GMP